7 studies found for:    "Enteropathy-associated T-cell lymphoma"
Show Display Options
Rank Status Study
1 Completed Study of MLN8237 in Patients With Advanced Hematological Malignancies
Conditions: B-cell Follicular Lymphoma;   B-cell Marginal Zone Lymphoma;   Diffuse Large B-cell Lymphoma;   B-cell Mantle Cell Lymphoma;   B-cell Small Lymphocytic Lymphoma (SLL);   B-Cell Chronic Lymphocytic Leukemia (B-CLL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS);   Angioimmunoblastic T-cell Lymphoma (AITL);   Anaplastic Large Cell Lymphoma;   Enteropathy Associated T-cell Lymphoma (EATCL);   NK Lymphoma (NKL)
Intervention: Drug: MLN8237
2 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
3 Completed Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
4 Unknown  High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: methotrexate;   Drug: prednisolone;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: biopsy;   Procedure: peripheral blood stem cell transplantation
5 Recruiting Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Everolimus
6 Completed SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
7 Terminated
Has Results
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib

Indicates status has not been verified in more than two years